Quercetin reduces COVID-19 risk: real-time meta-analysis of 12 studies (Version 22)

Significantly lower risk is seen for ICU admission, hospitalization, recovery, cases, and viral clearance. 11 studies from 9 independent teams in 7 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 46% [20‑64%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and after excluding studies using combined treatment and slightly worse for peer-reviewed studies.

Results are very robust—in worst case exclusion sensitivity analysis 9 of 12 studies must be excluded before statistical significance is lost.

Control Quercetin

Studies typically use advanced formulations for greatly improved bioavailability.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Dietary sources may be preferred. The quality of non-prescription supplements varies widely1-3. A lipid-optimized formulation may be required for therapeutic concentrations of quercetin. All data and sources to reproduce this analysis are in the appendix.

Other meta-analyses show significant improvements with quercetin for mortality4, ICU admission4,5, and hospitalization4,5.

2 meta-analyses show significant improvements with quercetin for mortality1, ICU admission1,2, and hospitalization1,2.